Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Neurology|February 22, 2024
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer DiseaseAdam S Fleisher, Leanne M Munsie, David G S Perahia, et al.Journal of Alzheimer'S Disease Reports|October 18, 2023
Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical TrialBrian A Willis, Albert C Lo, Jeffrey L Dage, et al.JAMA Neurology|September 12, 2022
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical TrialSergey Shcherbinin, Cynthia D Evans, Ming Lu, et al.The Journal of Prevention of Alzheimer'S Disease|May 27, 2026
Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analysesFrank Jessen, Grazia Dell'Agnello, Jennifer A Zimmer, et al.The Journal of Prevention of Alzheimer'S Disease|July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionHong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.Science Translational Medicine|October 13, 2021
Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumorsAnita C Bellail, Hong Ri Jin, Ho-Yin Lo, et al.Pageof 2